Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | STAT6 | P42226 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2487444 | 0.84 | CYP1A2 (0.51) | HSD17B10CYP2C9MCL1CYP1A2CYP3A4 | |
| SCHEMBL2789016 | 0.83 | CYP1A2 (0.50) | HSD17B10CYP1A2CYP3A4STAT6HIF1A | |
| Potassium Ion SCHEMBL10878677 | 0.82 | CYP1A2 (0.49) | HSD17B10CYP2C9MCL1CYP1A2CYP3A4 | |
| SCHEMBL31149178 | 0.80 | CYP1A2 (0.62) | HSD17B10CYP1A2CYP3A4STAT6HIF1A | |
| SCHEMBL245378 | 0.80 | CYP1A2 (0.62) | HSD17B10CYP1A2CYP3A4STAT6HIF1A | |
| SCHEMBL11573727 | 0.79 | CA1 (0.50) | HSD17B10CYP2C9MCL1CA1CA2 | |
| SCHEMBL28060760 | 0.77 | MEN1 (0.58) | HSD17B10CYP2C9CYP1A2CYP3A4STAT6 | |
| SCHEMBL7535526 | 0.77 | HSD17B10 (0.61) | HSD17B10CYP2C9MCL1CYP1A2CYP3A4 | |
| SCHEMBL5375009 | 0.75 | MEN1 (0.60) | HSD17B10CYP2C9CYP1A2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL11313207 | 0.75 | CYP1A2 (0.66) | HSD17B10CYP1A2CYP3A4STAT6HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029695-A1 | METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR | ASUBIO PHARMA CO., LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-7618977-B2 | Method of treating dermatitis comprising administering a chymase inhibitor | ASUBIO PHARMA CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-1142586-B1 | USE OF CHYMASE INHIBITORS AGAINST VASCULAR LIPID DEPOSITION | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-7169951-B2 | Quinazoline derivatives and pharmaceutical applications thereof | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2007-01-30 | — | — | US | disclosed |
| EP-1174151-B1 | THERAPEUTIC TREATMENT OF EOSINOPHILIA USING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2007-01-24 | — | — | EP | disclosed |
| EP-1192950-B1 | THERAPEUTIC DRUGS FOR DERMATITIS EXHIBITING A BIPHASIC SKIN REACTION CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-07-26 | — | — | EP | disclosed |
| EP-1114035-B1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-05-17 | — | — | EP | disclosed |
| US-6921766-B1 | Blood vessel lipid deposition-preventive agent comprising chymase-inhibitor | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-07-26 | — | — | US | disclosed |
| US-20050148608-A1 | Quinazoline derivatives and pharmaceutical applications thereof | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| US-6867214-B1 | Quinazoline derivatives and pharmaceutical applications thereof | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-03-15 | — | — | US | disclosed |
| US-6500835-B2 | FOR PROPHYLAXIS AND THERAPY OF FIBROSIS INVOLVING EXTRACELLULAR MATRIX DYSBOLISM HAVING A CHYMASE INHIBITOR AS AN EFFECTIVE INGREDIENT; SIDE EFFECT REDUCTION | SUNTORY LIMITED (JP) | 2002-12-31 | — | — | US | disclosed |
| US-20020187989-A1 | Preventive or therapeutic drugs for various eosinophilia-related diseases containg chymase inhibitors as the active ingredient | ASUBIO PHARMA CO., LTD. (JP) | 2002-12-12 | — | — | US | disclosed |
| US-20020183339-A1 | Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2002-12-05 | — | — | US | disclosed |
| US-20020183338-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR FIBROSIS CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | ASUBIO PHARMA CO., LTD. (JP) | 2002-12-05 | — | — | US | disclosed |
| EP-1192949-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR FIBROSIS CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2002-04-03 | — | — | EP | disclosed |
| EP-1192950-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR DERMATITISES CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2002-04-03 | — | — | EP | disclosed |
| EP-1174151-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR VARIOUS EOSINOPHILIA-RELATED DISEASES CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-1142586-A1 | INHIBITORS AGAINST VASCULAR LIPID DEPOSITION CONTAINING CHYMASE-INHIBITING SUBSTANCES | SUNTORY LIMITED (JP) | 2001-10-10 | — | — | EP | disclosed |
| EP-1114035-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF | SUNTORY LIMITED (JP) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000010982-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEROF | SUNTORY LIMITED (JP) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187989-A1 | Preventive or therapeutic drugs for various eosinophilia-related diseases containg chymase inhibitors as the active ingredient | CMA1, SERPINB1, EPX | HSD17B10 2394/4885CYP2C9 1334/4885MCL1 4072/4885 |
| US-20020183339-A1 | Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient | CMA1, SERPINB1, TSLP | HSD17B10 4522/4885CYP2C9 4163/4885MCL1 4067/4885 |
| US-20050148608-A1 | Quinazoline derivatives and pharmaceutical applications thereof | CMA1, ACE, ACE2 | HSD17B10 3157/4885CYP2C9 176/4885MCL1 4779/4885 |
| US-20020183338-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR FIBROSIS CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | CMA1, MMP1, SERPINB1 | HSD17B10 2699/4885CYP2C9 1239/4885MCL1 4849/4885 |
| US-20100029695-A1 | METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR | CMA1, DNPEP, SERPINB1 | HSD17B10 4202/4885CYP2C9 3908/4885MCL1 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.